Analysis of the Mechanism of Action of Biological Therapies in Monotherapy in Patients with Rheumatoid Arthritis: Beyond the ADACTA Study
|M Victoria Hernández1*, Silvia Vidal2 and Raimon Sanmarti1|
|1Arthritis Unit, Rheumatology Department, Hospital Clinic, University of Barcelona, Spain|
|2Immunology Department, Hospital Sant Pau, University Autonoma, Barcelona, Spain|
|*Corresponding Author :||M Victoria Hernández, MD, PhD
Arthritis Unit, Rheumatology Department
Hospital Clínic, Villarroel 170, stairway 11
2nd floor, 08036 Barcelona, Spain
Tel: + (34) 932275400 ext 2236
Fax: + (34) 934515173
E-mail: [email protected]
|Received August 23, 2013; Accepted September 20, 2013; Published September 23, 2013|
|Citation: Hernández MV, Vidal S, Sanmarti R (2013) Analysis of the Mechanism of Action of Biological Therapies in Monotherapy in Patients with Rheumatoid Arthritis: Beyond the ADACTA Study. Adv Pharmacoepidemiol Drug Saf 2:141. doi:10.4172/2167-1052.1000141|
|Copyright: © 2013 Hernández MV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
The recently-published first head-to-head study comparing the efficacy of two biological drugs on monotherapy, tocilizumab and adalimumab, found better results for tocilizumab. Both are cytokine-specific antagonists: adalimumab targets tumor necrosis factor and tocilizumab targets interleukin-6 receptor .
The aim of our review was to determine differences in the mechanisms of action of adalimumab and tocilizumab, in order to explain the differing results found, and to describe the immunologic and clinical aspects of the two drugs.